Ben Teller, survivor
Lymphoma is an umbrella term describing dozens of cancers that begin in the immune system. Lymphomas are the most common type of blood cancer, and are broadly categorized as either Hodgkin or non-Hodgkin disease. All lymphoma subtypes combined are the seventh most common cancer in the United States.
Getting treated for lymphoma at City of Hope gives you access to unparalleled treatment options and exceptional care from experts in all subtypes of the disease, from rare and unusual to complex and chronic. It means you are the focus of a team of world class scientific leaders who know the newest and best treatments for your disease – and likely played a role in their discovery. Some of the ways City of Hope researchers and clinicians at the Toni Stephenson Lymphoma Center are driving the lymphoma field forward include:
- Developing the technology behind rituximab, one of the most commonly prescribed immunotherapies used to treat lymphoma
- Leading research resulting in Food and Drug Administration approval of brentuximab vedotin, a treatment that is extending the lives of patients who failed previous therapies
- Innovating several immunotherapeutic approaches for treating lymphoma, including CAR T cell therapy
- Pioneering groundbreaking therapies for cutaneous lymphoma, including skin-directed and light therapies
- Leading research that is changing the standard of care for HIV and AIDS-related lymphomas
- Using innovative approaches for blood and bone marrow transplantation to treat lymphoma, leading to unrivaled survival rates